regorafenib following first-line systemic therapy in hcc
Published 5 years ago • 46 plays • Length 4:30Download video MP4
Download video MP3
Similar videos
-
4:32
first-line regorafenib 80mg/day with pembrolizumab in advanced hcc
-
7:01
global use of regorafenib in hcc
-
3:48
clinical experience with regorafenib in hcc
-
8:29
incorporating regorafenib in the hcc treatment landscape
-
2:53
renobate: investigating regorafenib plus nivolumab as 1st-line therapy for unresectable hcc
-
8:50
first-line therapy in advanced hcc
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc
-
0:49
dr. daniele on impact of regorafenib in hcc
-
3:17
second-line systemic therapy in hcc
-
1:28
dr. jordi bruix on efficacy and safety of regorafenib in hcc after sorafenib
-
5:27
second-line systemic therapy in hcc
-
2:04
dr. bruix on regorafenib in second-line hcc
-
7:57
optimizing sequencing of therapies in hcc
-
7:09
global use of regorafenib in hcc
-
2:52
refine: a real-world analysis of regorafenib in patients with unresectable hcc
-
6:02
hcc: considerations in first-line use of sorafenib
-
1:03
dr. musher discusses the role of regorafenib in advanced hcc
-
1:27
dr. sherman on the role of regorafenib in liver cancer
-
8:25
key takeaway 4: second-line regorafenib after tki in hcc